These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15739102)

  • 1. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli.
    Vail RB; Homann MJ; Hanna I; Zaks A
    J Ind Microbiol Biotechnol; 2005 Feb; 32(2):67-74. PubMed ID: 15739102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
    Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
    Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes.
    Zhang WV; D'Esposito F; Edwards RJ; Ramzan I; Murray M
    Drug Metab Dispos; 2008 Dec; 36(12):2547-55. PubMed ID: 18809730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
    Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
    Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone.
    Shou M; Korzekwa KR; Brooks EN; Krausz KW; Gonzalez FJ; Gelboin HV
    Carcinogenesis; 1997 Jan; 18(1):207-14. PubMed ID: 9054608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferrous and ferric state of cytochromes P450 in intact Escherichia coli cells: a possible role of cytochrome P450-flavodoxin interactions.
    Culka M; Milichovsky J; Jerabek P; Stiborova M; Martinek V
    Neuro Endocrinol Lett; 2015; 36 Suppl 1():29-37. PubMed ID: 26757119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
    Masubuchi Y; Horie T
    Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives.
    Shimada T; Tanaka K; Takenaka S; Murayama N; Martin MV; Foroozesh MK; Yamazaki H; Guengerich FP; Komori M
    Chem Res Toxicol; 2010 Dec; 23(12):1921-35. PubMed ID: 21053930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase.
    Gillam EM; Wunsch RM; Ueng YF; Shimada T; Reilly PE; Kamataki T; Guengerich FP
    Arch Biochem Biophys; 1997 Oct; 346(1):81-90. PubMed ID: 9328287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the interactions between drugs and estrogen: analytical method for prediction system of gynecomastia induced by drugs on the inhibitory metabolism of estradiol using Escherichia coli coexpressing human CYP3A4 with human NADPH-cytochrome P450 reductase.
    Satoh T; Fujita KI; Munakata H; Itoh S; Nakamura K; Kamataki T; Itoh S; Yoshizawa I
    Anal Biochem; 2000 Nov; 286(2):179-86. PubMed ID: 11067738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase.
    Dong MS; Yamazaki H; Guo Z; Guengerich FP
    Arch Biochem Biophys; 1996 Mar; 327(1):11-9. PubMed ID: 8615680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1, and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase.
    Oda Y; Aryal P; Terashita T; Gillam EM; Guengerich FP; Shimada T
    Mutat Res; 2001 May; 492(1-2):81-90. PubMed ID: 11377247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation.
    Ohyama K; Murayama N; Shimizu M; Yamazaki H
    Xenobiotica; 2014 Jan; 44(1):10-6. PubMed ID: 23777257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation.
    Duarte MP; Palma BB; Gilep AA; Laires A; Oliveira JS; Usanov SA; Rueff J; Kranendonk M
    Mutagenesis; 2005 Mar; 20(2):93-100. PubMed ID: 15728263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification, and characterization of a catalytically active human cytochrome P450 1A2:rat NADPH-cytochrome P450 reductase fusion protein.
    Parikh A; Guengerich FP
    Protein Expr Purif; 1997 Apr; 9(3):346-54. PubMed ID: 9126606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
    Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
    Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction.
    Fasinu PS; Bouic PJ; Rosenkranz B
    Afr J Tradit Complement Altern Med; 2014; 11(4):54-61. PubMed ID: 25392581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems.
    Guengerich FP; Johnson WW
    Biochemistry; 1997 Dec; 36(48):14741-50. PubMed ID: 9398194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.